Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 MAR 9 ... Study (ETDRS) and to assess the effect of the orally administered PKC beta inhibitor ruboxistaurin (RBX) on these parameters. In the PKC-DRS2, patients with moderately severe to very ...
2009 FEB 16 ... with diabetic retinopathy. Data are from a randomized, placebo-controlled trial of ruboxistaurin for vision loss in patients with diabetic retinopathy."
"Visual ...
2009 APR 20 ... activation of AP-1, and upregulation of TGF-beta 1. In vivo, the PKC-beta inhibitor ruboxistaurin prevented Akt activation in the renal cortex of diabetic rats," wrote D.C. Wu and ...
2009 JUN 29 ... reduction in atherosclerosis of similar to 2-fold was observed in apoE(-/-) mice fed ruboxistaurin chow (PKC beta inhibitor) vs. vehicle. In primary murine and human aortic endothelial ...
2009 MAR 2 ... the United Kingdom, " In PKC-DRS2, the efficacy of the oral PKC-beta inhibitor, ruboxistaurin 32 mg/day, was measured by the primary end point of sustained moderate visual loss ...
2009 JUL 13 ... (STNx) rats were randomly assigned to receive either the selective PKC-beta in-hibitor, ruboxistaurin or vehicle. In addition to functional and structural parameters, gene expression of the ...
2009 MAR 2 ... trial in type-2 diabetes was to assess the effect of the PKC beta-specific inhibitor, ruboxistaurin (32 mg/day for 6 weeks) on ultrasound assessed brachial artery flow mediated dilatation ...
2009 JUL 6 ... Diabetic rats were randomized to receive either vehicle or the PKC-beta inhibitor, ruboxistaurin (20 mg/kg per d) and followed for 6 weeks. Compared with untreated animals,...
2008 FEB 25 ... report.
"A new potential therapeutic agent, the PKC-beta inhibitor ruboxistaurin, has been studied in animal and human clinical trials in diabetic microvascular disease, ...
2008 SEP 8 ... towards certain ligands, despite their high sequence similarities."
"Ruboxistaurin is a specific inhibitor of PKC-beta. To understand the molecular determinants for the ...
2007 DEC 31 ... in placebo-administered patients from two 1-year studies in which the impact of ruboxistaurin (RBX) in mild diabetic peripheral neuropathy (DPN) was tested. Data from 262 ...
2008 MAY 26 ... "Homozygous PKCbeta-null (PKCbeta(-/-)) and wild-type mice fed the PKCbeta inhibitor ruboxistaurin displayed significantly decreased infarct size and enhanced recovery of left ventricular ...
2008 MAR 3 ... report.
"A new potential therapeutic agent, the PKC-beta inhibitor ruboxistaurin, has been studied in animal and human clinical trials in diabetic microvascular disease, ...
2008 MAR 31 ... nephropathy, including aggressive RAAS blockade, statins, pentoxifylline, glitazones, ruboxistaurin, as well as sulodexide. Pilot studies that used surrogate end points, mainly ...
2007 DEC 17 ... neuropathy. The oral PKC inhibitor midostaurin and oral selective PKC beta inhibitor ruboxistaurin appear promising for improving or maintaining visual acuity, with gastrointestinal ...
2008 JUN 16 ... followed by laser may be more effective than intravitreal triamcinolone acetonide alone. Ruboxistaurin, a selective protein kinase C beta inhibitor, reduced retinal vascular leakage in ...
